Early Data Send Strong Signal in Advanced Gyn Cancers

March 19, 2019 7:00 pm

By Ian Ingram

Clinical benefit rate tops 90% in pair of single-center studies.

Two early trials of novel combinations showed promising clinical activity in gynecologic cancers at a late-breaking abstract session at the Society of Gynecologic Oncology (SGO) meeting here.… Read more

SGO 2019: Pembrolizumab Combo Shows Clinical Benefit for Recurrent Epithelial Ovarian Cancer

March 19, 2019 3:00 pm

By Christina Bennett, MS

Pembrolizumab in combination with bevacizumab and oral metronomic cyclophosphamide showed clinical activity in patients with recurrent epithelial ovarian cancer, according to the results of an open-label phase II trial (LBA4) presented at the 2019 Society of … Read more

The First-Ever Clinical Trial Using Tocotrienols with Ovarian Cancer Patients, Increased their Survival by Seventy Percent in Refractory Ovarian Cancer

February 7, 2019 3:00 pm

A recent study conducted at Denmark’s Vejle Hospital, published in Pharmacological Research, provides evidence of delta-tocotrienol’s benefits for cancer patients. Results of the open-label trial suggest that American River Nutrition-manufactured delta-tocotrienol in combination with bevacizumab had additive effects in chemotherapy … Read more

Bevacizumab Rechallenge Benefit in Recurrent Ovarian Cancer?

June 19, 2018 5:43 pm

A new study suggests that a rechallenge with bevacizumab in combination with platinum-based chemotherapy may prolong progression-free survival (PFS) in patients with recurrent ovarian cancer (ROC) who already received this agent during first-line treatment. The study was presented by Italian … Read more

FDA Approves Bevacizumab Plus Chemotherapy in Advanced OC

June 14, 2018 7:32 pm

Today, the U.S. Food and Drug Administration (FDA) approved bevacizumab (Avastin) in combination with chemotherapy (carboplatin and paclitaxel) followed by bevacizumab as a single agent for the treatment of women with advanced (stage III or IV) ovarian cancer following initial … Read more

PFS Rises in Ovarian Cancer with Repeat Bevacizumab

June 8, 2018 9:47 pm

Women with advanced ovarian cancer previously treated with bevacizumab (Avastin) had a 3-month improvement in progression-free survival (PFS) when they received second-line therapy that included bevacizumab, European investigators reported.

Median PFS increased from 8.8 months with platinum-based chemotherapy to 11.8 … Read more

Women with Ovarian Cancer Who May Benefit from Maintenance Treatment

January 15, 2018 6:18 pm

Myriad Genetics and AstraZeneca have expanded their collaboration to conduct a study to identify women with advanced ovarian cancer who may benefit from maintenance treatment with Lynparza (olaparib) and Avastin (bevacizumab).

Myriad’s myChoice HRD Plus is a test for BRCA1 … Read more

Adding Bevacizumab to Chemo May Prolong Survival

May 8, 2017 8:58 pm

Adding bevacizumab to platinum-based chemotherapy may improve survival among women with recurrent ovarian cancer, according to a study published in Lancet Oncology.1

Bevacizumab is emerging as an effective strategy as a first-line or maintenance therapy for recurrent ovarian … Read more

Avastin Gains Expanded FDA Approval for Platinum-Sensitive Ovarian Cancer

December 8, 2016 7:04 pm

Avastin (bevacizumab) gained an expanded FDA approval to treat patients with platinum-sensitive recurrent ovarian cancer as a part of a combination regimen with chemotherapy followed by continued use of the angiogenesis inhibitor, according to the drug developer, Genentech.

The approval … Read more